Vaccine Academy › Vaccine School › Childhood and adolescent
Content current as of October 11, 2026. AI-assisted draft; not yet reviewed by a licensed pharmacist. Current CDC schedules: immunization schedules.
- The disease and why it matters
- Video and figures
- Get CE credit
- Products available
- Who should get it
- Dosing and schedule, including catch-up
- Administration
- Storage and handling
- Contraindications and precautions
- Safety and adverse events
- Special populations
- Counseling pearls for the pharmacy counter
- Common patient questions
- References
The disease and why it matters
Meningococcal disease is an uncommon but very serious infection caused by Neisseria meningitidis; the two most common syndromes are meningitis and septicemia. [1]
Serogroups B, C and Y cause the majority of disease in the United States; serogroup W and nongroupable strains cause a small portion. [1]
People spread the bacteria by exchanging respiratory and throat secretions during close or lengthy contact; people with disease and people who carry the bacteria asymptomatically in the nasopharynx can spread them, and humans are the only host. [1]
Even when treated, meningococcal disease kills 10 to 15 of every 100 infected people, and about 10 to 20 of every 100 survivors suffer disabilities such as hearing loss, brain damage, kidney damage, loss of limbs, nervous system problems or severe scars from skin grafts. [2]
Cases of meningococcal disease in the United States have increased sharply since 2021 and now exceed pre-pandemic levels; people disproportionately affected include those aged 30 to 60 years, Black or African American people and adults with HIV. [1] [3]
Age groups with higher rates of disease than other ages are infants younger than one year, adolescents and young adults 16 through 23 years, and adults 85 years or older. [1]
Video and figures
Video
Get CE credit
- CDC You Call the Shots: Meningococcal module (CDC TRAIN course WB4594R) — CDC · Free (CDC states no fees for its CE activities) · accredited by CDC, jointly accredited by ACCME, ACPE and ANCC; pharmacy UAN JA4008229-0000-22-061-H06-P. CDC's listing shows credit expiring 6/15/2026, so confirm on CDC TRAIN that credit is still available · link confirmed October 11, 2026
RxEvidence is not an accredited continuing education provider and does not award CE credit. These are links to activities offered by others.
Products available
CDC states that the United States uses three types of meningococcal vaccines, each protecting against different serogroups: MenACWY (serogroups A, C, W and Y), MenB (serogroup B) and MenABCWY (all five); its list of the 6 meningococcal vaccines now available names Menveo and MenQuadfi as the MenACWY vaccines. [4] [5]
| Vaccine | Manufacturer (FDA page) | FDA-approved use | Initial U.S. approval |
|---|---|---|---|
| Menveo (MenACWY-CRM) | GlaxoSmithKline Biologicals [6] | Active immunization to prevent invasive meningococcal disease caused by N. meningitidis serogroups A, C, Y and W-135 in individuals 2 months through 55 years of age; does not prevent serogroup B infection [7] | 2010 [7] |
| MenQuadfi (MenACWY-TT) | Sanofi Pasteur, Inc. [8] | Active immunization for the prevention of invasive meningococcal disease caused by serogroups A, C, W and Y in individuals 6 weeks of age and older; does not prevent serogroup B disease [9] | 2020 [9] |
| Menactra (MenACWY-D) | Sanofi Pasteur Inc [10] | Active immunization to prevent invasive meningococcal disease caused by serogroups A, C, Y and W-135 in individuals 9 months through 55 years of age; does not prevent serogroup B disease [11] | 2005 [11] |
CDC's Pink Book chapter (page dated April 25, 2024) lists three quadrivalent meningococcal conjugate vaccines licensed for use in the United States (Menactra, Menveo and MenQuadfi), but CDC's later vaccine-types page (March 30, 2026) lists only Menveo and MenQuadfi as the MenACWY vaccines now available; the FDA Menactra page (content current as of 11/19/2019) and its April 2018 label remain posted. This lesson does not state why Menactra is absent from CDC's list, because none of the sources opened say so. [12] [5] [10] [11]
Menveo is supplied in two presentations: a two-vial presentation (a liquid MenCYW-135 component with a gray cap and a lyophilized MenA component with an orange cap, combined before use) for ages 2 months through 55 years, and a one-vial presentation (pink cap) that needs no reconstitution, for ages 10 through 55 years. [7]
The Menveo label posted on FDA's page shows a placeholder revision date ("xx/202x"), while FDA's Menveo page lists a March 31, 2025 approval letter and is marked content current as of 05/14/2025. [7] [6]
Who should get it
CDC / ACIP (meningococcal vaccine recommendations page, March 30, 2026)
As of March 30, 2026
CDC recommends that all 11- to 12-year-old adolescents receive a MenACWY vaccine, with a booster dose at age 16 years; if the initial dose was given at ages 13 through 15 years, a booster at ages 16 through 18 years is recommended, and if it was given at age 16 or older no booster is recommended. [4]
CDC July 2, 2025 child and adolescent schedule notes
As of July 2, 2025
The July 2025 schedule notes list routine vaccination as a 2-dose series at age 11 to 12 years and 16 years, and catch-up as 1 dose now with a booster at 16 to 18 years (minimum interval 8 weeks) for ages 13 to 15 and 1 dose for ages 16 to 18. [13]
The CDC risk-indications page lists these factors for MenACWY vaccination: complement component deficiency, functional or anatomic asplenia (including sickle cell disease), HIV, complement inhibitors (for example Soliris and Ultomiris), travel to or residence in countries where serogroup A, C, W or Y disease is common, routine exposure to N. meningitidis as a microbiologist, military recruit, a first-year college student living in a residence hall who is not up to date, and being part of a community with a serogroup A, C, W or Y outbreak. [14]
CDC / ACIP and the FDA labels compared on minimum age
As of July 2, 2025
CDC's child schedule notes (July 2, 2025) give a minimum age of 2 months for Menveo and 2 years for MenQuadfi, and CDC's Pink Book chapter (April 25, 2024) says MenQuadfi is approved for persons 2 years or older. [13] [12]
FDA MenQuadfi prescribing information (revised 5/2025)
As of May 1, 2025
The MenQuadfi label lists an indication for individuals 6 weeks of age and older and includes a 4-dose infant series starting as early as 6 weeks; the label's "Recent major changes" lists the Indications and Dosage and Administration sections as changed 5/2025. This is a difference between CDC's July 2025 schedule notes and the current FDA label, and the pages opened do not explain it. [9]
In adults, CDC's July 2025 schedule notes recommend MenACWY for those with asplenia, HIV, persistent complement component deficiency or complement inhibitor use; for travelers to countries with hyperendemic or epidemic disease and for microbiologists routinely exposed to N. meningitidis; and for first-year college students living in residential housing (if not previously vaccinated at age 16 years or older) and military recruits. [15]
CDC: January 2026 schedule revision and its legal status (MenACWY)
As of June 11, 2026
On January 5, 2026 the CDC Acting Director approved a revised childhood and adolescent schedule that changed the recommendation type for hepatitis A, meningococcal ACWY and RSV vaccines from a full recommendation for all children to a risk-based recommendation for children at high risk, with shared clinical decision-making for other children; the schedule's first category (recommended for all children) lists measles, mumps, rubella, polio, pertussis, tetanus, diphtheria, Hib, pneumococcal disease, HPV and varicella. A federal district court stayed that schedule on March 16, 2026 and reverted it to the version as of May 2025, and CDC's schedule page continues to show the July 2, 2025 addendum edition. [16] [17] [18]
American Academy of Pediatrics 2026 schedule (endorsed by AAFP, ACOG, AMA, IDSA, APhA and others)
As of January 26, 2026
The AAP published its own 2026 schedule on January 26, 2026, which continues to recommend routine immunization for protection against 18 diseases, including RSV, hepatitis A, hepatitis B, rotavirus, influenza and meningococcal disease, and differs from the schedule recently issued by CDC; the AAP schedule is formally endorsed by 12 organizations, including AAFP, ACOG, AMA, IDSA and the American Pharmacists Association. [19]
Dosing and schedule, including catch-up
| Age at first dose | Menveo | MenQuadfi | Menactra |
|---|---|---|---|
| Infants starting at 2 months | 4-dose series at 2, 4, 6 and 12 months of age [7] | 4-dose series at 2, 4, 6 and 12 through 18 months; first dose as early as 6 weeks [9] | Not approved below 9 months (indicated from 9 months of age) |
| Children 7 or 6 months through 23 months | 7 through 23 months: 2-dose series, second dose in the second year of life and at least 3 months after the first [7] | 6 through 11 months: 2-dose series with the second dose in the second year of life and at least 3 months after the first; 12 through 23 months: 2 doses at least 3 months apart [9] | 9 through 23 months: two doses, three months apart [11] |
| Individuals 2 years and older | 2 through 55 years: a single dose [7] | 2 years and older: a single dose [9] | 2 through 55 years: a single dose [11] |
| Booster (label) | Single booster for ages 15 through 55 at continued risk if at least 4 years since the prior dose [7] | Single dose for ages 13 and older at continued risk if at least 3 years since a prior MenACWY conjugate dose [9] | Single booster for ages 15 through 55 at continued risk if at least 4 years since the prior dose [11] |
For people at increased risk, CDC recommends a 2- to 4-dose primary series starting at 2 months of age and regular booster doses if risk remains: for those under 7 years, a booster 3 years after completing the primary series and every 5 years thereafter; for those 7 years or older, a booster every 5 years. [4]
During an outbreak caused by serogroup A, C, W or Y, previously vaccinated people who are part of the population at increased risk should receive a booster dose if 5 or more years have passed since the most recent MenACWY vaccine. [4]
| Age at first dose | Schedule |
|---|---|
| 2 months (Menveo) | 4-dose series (additional 3 doses at age 4, 6 and 12 months) [13] |
| 3 to 6 months (Menveo) | 3- or 4-dose series (dose 2 [and dose 3 if applicable] at least 8 weeks after previous dose until a dose is received at age 7 months or older, followed by an additional dose at least 12 weeks later and after age 12 months) [13] |
| 7 to 23 months (Menveo) | 2-dose series (dose 2 at least 12 weeks after dose 1 and after age 12 months) [13] |
| 24 months or older (Menveo or MenQuadfi) | 2-dose series at least 8 weeks apart [13] |
CDC's clinical guidance page says that for people with HIV, recommended MenACWY vaccination includes a 2-dose primary series and booster doses every 3 to 5 years depending on age. [3]
Administration
- Menveo and MenQuadfi are given as a single 0.5-mL intramuscular injection; inspect for particulate matter and discoloration and do not administer if present. [7] [9]
- Menveo two-vial presentation: use the liquid MenCYW-135 component (Vial 1, gray cap) to reconstitute the lyophilized MenA component (Vial 2, orange cap), invert and shake well until dissolved, withdraw 0.5 mL, and administer immediately after reconstitution. [7]
- Menveo one-vial presentation (pink cap) does not require reconstitution; withdraw 0.5 mL from the vial. [7]
- CDC's notes say the liquid (single-vial) formulation of Menveo should not be used before age 10 years. [13]
- Do not mix Menveo or any of its components with any other vaccine or diluent in the same syringe or vial. [7]
- MenACWY vaccines may be given simultaneously with MenB vaccines if indicated, at a different anatomic site if feasible. [15]
- Menactra, Menveo or MenQuadfi can be given at the same visit as other indicated vaccines, with one exception: in people with anatomic or functional asplenia or HIV, Menactra and PCV13 should not be given simultaneously, and Menactra should not be given until at least 4 weeks after completion of all PCV13 doses. [12]
- In children at increased risk, Menactra should be given either before or at the same time as DTaP to avoid interference with the meningococcal immune response. [12]
- If only the liquid C-W-Y component of Menveo is administered by mistake, revaccination may not be needed unless the person is traveling internationally, especially to Africa; a properly reconstituted Menveo dose or a dose of Menactra or MenQuadfi should then be given, with no minimum interval after the incomplete dose. [12]
Storage and handling
- Menveo (before reconstitution): store refrigerated, away from the freezer compartment, at 36 to 46 °F (2 to 8 °C); do not freeze, discard frozen or previously frozen product; protect from light; maintain at 2 to 8 °C during transport; do not use after the expiration date. [7]
- MenQuadfi: store at 2 to 8 °C (35 to 46 °F); do not freeze; do not use vaccine that has been frozen or after the expiration date. [9]
- Menactra: store at 2 to 8 °C (35 to 46 °F); do not freeze; frozen or previously frozen product should not be used. [11]
- The Menveo and MenQuadfi vial stoppers are not made with natural rubber latex. [7] [9]
Contraindications and precautions
| Item | Statement | Source |
|---|---|---|
| MenACWY, all products | Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component. [20] | CDC appendix |
| Menveo only | Severe allergic reaction to any diphtheria toxoid- or CRM197-containing vaccine; preterm birth if younger than age 9 months (listed as a precaution). [20] | CDC appendix |
| MenQuadfi only | Severe allergic reaction to a tetanus toxoid-containing vaccine. [20] | CDC appendix |
| Precaution | Moderate or severe acute illness with or without fever. [20] | CDC appendix |
| Menveo label | Severe allergic reaction (e.g., anaphylaxis) to a previous dose of Menveo, to any component of the vaccine, or to any other diphtheria toxoid-containing vaccine. [7] | FDA label |
| MenQuadfi label | Severe allergic reaction to any component of the vaccine, or after a previous dose of MenQuadfi or any other tetanus toxoid-containing vaccine. [9] | FDA label |
| Menactra label | Severe allergic reaction (e.g., anaphylaxis) after a previous dose of a meningococcal capsular polysaccharide-, diphtheria toxoid- or CRM197-containing vaccine, or to any component of Menactra. [11] | FDA label |
Safety and adverse events
Menveo: common solicited adverse reactions (10% or more) in adolescents and adults after a single dose were pain at the injection site (41%), headache (30%), myalgia (18%), malaise (16%) and nausea (10%); in children aged 2 through 10 years they were injection-site pain (31%), erythema (23%), irritability (18%), induration (16%), sleepiness (14%), malaise (12%) and headache (11%). [7]
Menveo in infants starting at 2 months (4-dose series): tenderness (24% to 41%), injection-site erythema (11% to 15%), irritability (42% to 57%), sleepiness (29% to 50%), persistent crying (21% to 41%), change in eating habits (17% to 23%), vomiting (5% to 11%) and diarrhea (8% to 16%). [7]
MenQuadfi: the most commonly reported adverse reactions (10% or more) were injection-site pain (38.6%), erythema (22.6%) and swelling (13.8%), malaise (21.1%), myalgia (20.1%) and headache (12.5%) in children 2 through 9 years; injection-site pain (34.8% to 45.2%), myalgia (27.4% to 35.3%), headache (26.5% to 30.2%) and malaise (19.4% to 26.0%) in adolescents 10 through 17 years; and injection-site pain (41.9%), myalgia (35.6%), headache (29.0%) and malaise (22.9%) in adults 18 through 55 years. [9]
Syncope has occurred in association with administration of Menveo and may occur with MenQuadfi; procedures should be in place to avoid injury from fainting. [7] [9]
Guillain-Barré syndrome (GBS) has been reported in temporal relationship following administration of another U.S.-licensed quadrivalent meningococcal polysaccharide conjugate vaccine, and the decision to give Menveo or MenQuadfi to people with a history of GBS should take into account expected benefits and potential risks; the Menactra label says persons previously diagnosed with GBS may be at increased risk of GBS following Menactra. [7] [9] [11]
Apnea following intramuscular vaccination has been observed in some infants born prematurely; the decision about when to give Menveo to a premature infant should be based on the infant's medical status and the potential benefits and risks. [7]
Report suspected adverse reactions to VAERS at 1-800-822-7967 (also GlaxoSmithKline at 1-888-825-5249 for Menveo, Sanofi Pasteur at 1-800-822-2463 for MenQuadfi and Menactra). [7] [9] [11]
Special populations
Complement deficiency and complement inhibitors: people with certain complement deficiencies and people receiving treatment that inhibits terminal complement activation (for example eculizumab) are at increased risk for invasive meningococcal disease, including disease caused by serogroups A, C, W and Y, even if they develop antibodies after vaccination. [9]
CDC says vaccines and antimicrobial prophylaxis likely provide incomplete protection for patients receiving eculizumab or ravulizumab, and these patients should seek medical care immediately for meningococcal disease symptoms regardless of vaccination status or antibiotic use. [1]
Immunocompromised people: some individuals with altered immunocompetence, including some receiving immunosuppressant therapy, may have reduced immune responses to MenQuadfi and Menveo. [9] [7]
Pregnancy and breastfeeding: CDC's VIS says there is limited information on the risks of this vaccine for pregnant or breastfeeding women but no safety concerns have been identified, and a pregnant or breastfeeding woman should be vaccinated if indicated. [2]
The Menveo label cites a pregnancy exposure registry (2014 to 2017) of 82 pregnancies with exposure within 28 days before conception or during pregnancy in which available data do not suggest an increased risk of major birth defects and miscarriage; the MenQuadfi label states that available human data are insufficient to inform vaccine-associated risks in pregnancy. [7] [9]
Adults 56 years and older: MenQuadfi, but not Menactra or Menveo, is licensed for use in adults 56 years or older, although any of these vaccines can be used to vaccinate people in this age group who are recommended to receive a quadrivalent meningococcal vaccine because of increased risk. [12]
Counseling pearls for the pharmacy counter
- Adolescents need 2 doses of MenACWY vaccine: the first at 11 or 12 years and a booster at 16 years. [2]
- Available data suggest that protection from MenACWY vaccines decreases in many teens within 5 years, so the 16-year-old booster is critical. [5]
- MenACWY vaccines do not protect against serogroup B disease; a different meningococcal vaccine is available for serogroup B. [2]
- Tell the vaccination provider about an allergic reaction after a previous dose or any severe, life-threatening allergy; people with minor illnesses may be vaccinated, while moderately or severely ill people should usually wait. [2]
- Redness or soreness where the shot is given can happen; a small percentage of people experience muscle pain, headache or tiredness; people sometimes faint after vaccination. [2]
- Vaccination is not a substitute for tetanus immunization: MenQuadfi does not substitute for routine tetanus immunization, and vaccination may not protect all recipients. [9]
Common patient questions
A 17-year-old received the first MenACWY dose at 16. Is a booster needed?
No. CDC says that if the initial vaccine was given at age 16 or older, a booster dose is not recommended (for a person not at increased risk). [4]
A 14-year-old was vaccinated at age 11 with a single dose. What now?
The booster is due at 16; CDC's July 2025 notes list a booster at age 16 years for routine vaccination (a 2-dose series at 11 to 12 years and 16 years). [13]
Can MenACWY and MenB be given on the same day?
Yes. They may be given simultaneously at different anatomic sites if feasible, and CDC says an MenABCWY vaccine is an option when both are due at the same visit. [15] [4]
Does a patient on eculizumab or ravulizumab need MenACWY?
Yes, complement inhibitors are listed among the indications for MenACWY, but CDC cautions that vaccination and antimicrobial prophylaxis likely provide incomplete protection, so these patients should seek care immediately for symptoms. [14] [1]
What is the booster interval for an asplenic adult?
CDC's July 2025 adult notes list a 2-dose primary series at least 8 weeks apart, then 1 booster dose 5 years after the primary series and every 5 years if risk remains. [15]
References
- Centers for Disease Control and Prevention. Clinical overview of meningococcal disease. Page dated March 30, 2026. Accessed October 11, 2026. https://www.cdc.gov/meningococcal/hcp/clinical/index.html. Accessed October 11, 2026.
- Centers for Disease Control and Prevention. Meningococcal ACWY vaccine: what you need to know. Vaccine Information Statement, January 31, 2025. Accessed October 11, 2026. https://www.cdc.gov/vaccines/hcp/current-vis/meningococcal-acwy.html. Accessed October 11, 2026.
- Centers for Disease Control and Prevention. Clinical guidance for meningococcal disease. Page dated June 4, 2026. Accessed October 11, 2026. https://www.cdc.gov/meningococcal/hcp/clinical-guidance/index.html. Accessed October 11, 2026.
- Centers for Disease Control and Prevention. Meningococcal vaccine recommendations (for health care providers). Page dated March 30, 2026. Accessed October 11, 2026. https://www.cdc.gov/meningococcal/hcp/vaccine-recommendations/index.html. Accessed October 11, 2026.
- Centers for Disease Control and Prevention. Types of meningococcal vaccines. Page dated March 30, 2026. Accessed October 11, 2026. https://www.cdc.gov/meningococcal/vaccines/types.html. Accessed October 11, 2026.
- U.S. Food and Drug Administration. MENVEO product page (content current as of 05/14/2025). Accessed October 11, 2026. https://www.fda.gov/vaccines-blood-biologics/vaccines/menveo. Accessed October 11, 2026.
- MENVEO [meningococcal (groups A, C, Y, and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine], solution for intramuscular injection: prescribing information as posted on FDA's product page (revision date shown as a placeholder, "xx/202x"). GlaxoSmithKline Biologicals. U.S. Food and Drug Administration. Accessed October 11, 2026. https://www.fda.gov/media/78514/download?attachment. Accessed October 11, 2026.
- U.S. Food and Drug Administration. MenQuadfi product page (content current as of 07/03/2025). Accessed October 11, 2026. https://www.fda.gov/vaccines-blood-biologics/menquadfi. Accessed October 11, 2026.
- MenQuadfi (meningococcal [groups A, C, Y, W] conjugate vaccine), injection for intramuscular use: prescribing information, revised 5/2025. Sanofi Pasteur Inc. U.S. Food and Drug Administration. Accessed October 11, 2026. https://www.fda.gov/media/137306/download?attachment. Accessed October 11, 2026.
- U.S. Food and Drug Administration. Menactra product page (content current as of 11/19/2019). Accessed October 11, 2026. https://www.fda.gov/vaccines-blood-biologics/vaccines/menactra. Accessed October 11, 2026.
- Menactra (meningococcal [groups A, C, Y and W-135] polysaccharide diphtheria toxoid conjugate vaccine), solution for intramuscular injection: prescribing information, revised April 2018. Sanofi Pasteur Inc. U.S. Food and Drug Administration. Accessed October 11, 2026. https://www.fda.gov/media/75619/download?attachment. Accessed October 11, 2026.
- Centers for Disease Control and Prevention. Meningococcal disease. In: Epidemiology and Prevention of Vaccine-Preventable Diseases (Pink Book), chapter 14. Page dated April 25, 2024. Accessed October 11, 2026. https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-14-meningococcal-disease.html. Accessed October 11, 2026.
- Centers for Disease Control and Prevention. Child and adolescent immunization schedule notes: recommendations for ages 18 years or younger, United States, 2025. July 2, 2025. Accessed October 11, 2026. https://www.cdc.gov/vaccines/hcp/imz-schedules/child-adolescent-notes.html. Accessed October 11, 2026.
- Centers for Disease Control and Prevention. Meningococcal vaccine risk indications. Page dated March 16, 2026. Accessed October 11, 2026. https://www.cdc.gov/meningococcal/hcp/vaccine-recommendations/risk-indications.html. Accessed October 11, 2026.
- Centers for Disease Control and Prevention. Adult immunization schedule notes: recommendations for ages 19 years or older, United States, 2025. July 2, 2025. Accessed October 11, 2026. https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-notes.html. Accessed October 11, 2026.
- Congressional Research Service. The 2026 Childhood Immunization Schedule (R48982). June 11, 2026. Accessed October 11, 2026. https://www.congress.gov/crs_external_products/R/PDF/R48982/R48982.1.pdf. Accessed October 11, 2026.
- Centers for Disease Control and Prevention. CDC acts on Presidential Memorandum to update childhood immunization schedule. News release, January 5, 2026. Accessed October 11, 2026. https://www.cdc.gov/media/releases/2026/2026-cdc-acts-on-presidential-memorandum-to-update-childhood-immunization-schedule.html. Accessed October 11, 2026.
- Centers for Disease Control and Prevention. Healthcare professionals: immunization schedules. Accessed October 11, 2026. https://www.cdc.gov/vaccines/hcp/imz-schedules/index.html. Accessed October 11, 2026.
- American Academy of Pediatrics. AAP releases recommended childhood and adolescent immunization schedule for 2026. HealthyChildren.org news. Accessed October 11, 2026. https://healthychildren.org/English/news/Pages/AAPs-recommended-childhood-and-adolescent-immunization-schedule-for-2026.aspx. Accessed October 11, 2026.
- Centers for Disease Control and Prevention. Child and adolescent immunization schedule appendix: contraindications and precautions (July 2, 2025 edition). Accessed October 11, 2026. https://www.cdc.gov/vaccines/hcp/imz-schedules/child-adolescent-appendix.html. Accessed October 11, 2026.
For professional education. Check current labeling and guidance before acting. Not medical advice.
